Johnson and Johnson 2006 Annual Report Download - page 17

Download and view the complete annual report

Please find page 17 of the 2006 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

N O V E L D I A G N O S T I C S “We’re working to identify novel diagnostic and prognostic markers,” says Yixin Wang (left), Ph.D.,
Executive Director, Research & Development at Veridex. “The genetic detective . . . [looks] for DNA that should not be
present, DNA that indicates the spread of cancer,” explains David Atkins (right), Ph.D., Vice President, EMEA for
Ortho-Clinical Diagnostics, Inc., who led the early development of GENESEARCH™.
markers, when validated, will become the foundation for new,
high-value diagnostic tests—tests that have the potential to
identify disease states at earlier stages than ever before.
CELLSEARCH™—unveiled in 2004—identifies, enumerates
and characterizes circulating tumor cells directly from a
whole-blood sample. It is currently available in the U.S. for use
in metastatic breast cancer, and clinical trials are in progress
for application with additional cancers.
STILL MORE TO COME Working as a project leader with
Atkins on GENESEARCH™ was Yixin Wang, Ph.D., Executive
Director, Research & Development at Veridex. Says Wang:
“The researchers in La Jolla are working to expand both
GENESEARCH™ and CELLSEARCH™ to facilitate early detection
of cancers. And we’re also working to identify novel diagnostic
and prognostic markers for major types of cancer to support
the Veridex molecular testing pipeline.”
Wang’s other Ortho-Clinical responsibility is to support
pharmaceutical research and development teams in biomarker
evaluation for drug development.
“The name of the game is detecting cancer cells at
the earliest possible point,” says Wang. “That’s what the
GENESEARCH™ and CELLSEARCH™ platforms are
designed to do. We look forward to bringing a series of
GENESEARCH™ and CELLSEARCH™ tests to market.”
“Our collective long-term dream at Ortho-Clinical and
Veridex,” says Davis, “is a world in which cancer is rarely
fatal, where diabetes never becomes full-blown and where
heart attacks are circumvented through early detection.
The European introduction of the GENESEARCH™ BLN
test is a testament that we are on our way to making the
dream a reality.”
T H E P O W E R O F K N O W I N G 15